(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.42%) $924.40
(0.38%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
4 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.20%
Live Chart Being Loaded With Signals
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults...
Stats | |
---|---|
本日の出来高 | 41 555.00 |
平均出来高 | 54 452.00 |
時価総額 | 131.23M |
EPS | $0 ( 2024-03-07 ) |
次の収益日 | ( $-0.220 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.790 |
ATR14 | $0.0100 (1.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Tasse Daniel | Buy | 17 094 | Ordinary Shares |
2024-02-06 | Ndu Adora | Buy | 1 825 | Ordinary Shares |
2023-11-22 | Mohideen Pharis | Sell | 2 245 | Ordinary Shares |
2023-11-20 | Boucinha Virginie | Buy | 113 000 | Employee Stock Option (right to buy) |
2023-11-20 | Boucinha Virginie | Buy | 19 000 | Ordinary Shares |
INSIDER POWER |
---|
99.86 |
Last 57 transactions |
Buy: 29 162 445 | Sell: 1 080 406 |
DBV Technologies S.A. 相関
10 最も負の相関 | |
---|---|
INCY | -0.916 |
SRTS | -0.904 |
FARO | -0.897 |
BXRX | -0.896 |
NWL | -0.895 |
CDXS | -0.892 |
NURO | -0.888 |
AYTU | -0.888 |
RCKY | -0.886 |
SBAC | -0.88 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
DBV Technologies S.A. 財務諸表
Annual | 2023 |
収益: | $15.73M |
総利益: | $20.23M (128.59 %) |
EPS: | $-0.380 |
FY | 2023 |
収益: | $15.73M |
総利益: | $20.23M (128.59 %) |
EPS: | $-0.380 |
FY | 2022 |
収益: | $4.80M |
総利益: | $-16.53M (-344.46 %) |
EPS: | $-0.620 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.890 |
Financial Reports:
No articles found.
DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。